{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:00:45Z","timestamp":1792404045426,"version":"4.4.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>A fast and easy-to-use liquid chromatography-tandem mass spectrometry method for the determination and quantification of 6 triazoles [fluconazole (FLZ), isavuconazole (ISZ), itraconazole (ITZ), hydroxy-itraconazole (OH-ITZ), posaconazole (PSZ), and voriconazole (VRZ)] in human plasma and serum was developed and validated for therapeutic drug monitoring.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Sample preparation was based on protein precipitation with acetonitrile and subsequent centrifugation. Isotope-labeled analogues for each analyte were used as internal standards. Chromatographic separation was achieved using a 50 \u00d7 2.1 mm, 1.9 \u03bcm polar Hypersil Gold C18 column and mobile phase consisting of 0.1% formic acid\/acetonitrile (45%\/55%, vol\/vol) at a flow rate of 340 \u03bcL\/min. The triazoles were simultaneously detected using a triple-stage quadrupole mass spectrometer operated in selected reaction monitoring mode with positive heated electrospray ionization within a single runtime of t = 3.00 minutes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Linearity of all azole concentration ranges was verified by the Mandel test and demonstrated for all azoles. All calibration curves were linear and fitted using least squares regression with a weighting factor of the reciprocal concentration. Limits of detection (\u03bcg\/L\/L) were FLZ, 9.3; ISZ, 0.3; ITZ, 0.6; OH-ITZ, 8.6; PSZ, 3.4; and VRZ, 2.1. The lower limits of quantitation (\u03bcg\/L\/liter) were FLZ, 28.3; ISZ, 1.0; ITZ, 1.7; OH-ITZ, 26.2; PSZ, 10.3; and VRZ, 6.3. Intraday and interday precisions ranged from 0.6% to 6.6% for all azoles. Intraday and interday accuracies (%bias) of all analytes were within 10.5%. In addition, we report on a 29-year-old white woman (94 kg body weight) with a history of acute myeloid leukemia who underwent stem cell transplantation. Because of diagnosis of aspergillus pneumonia, antifungal pharmacotherapy was initiated with different application modes and dosages of ISZ, and plasma concentrations were monitored over a time period of 6 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>A precise and highly sensitive liquid chromatography-tandem mass spectrometry method was developed that enables quantification of triazoles in plasma and serum matrix across therapeutically relevant concentration ranges. It was successfully implemented in our therapeutic drug monitoring routine service and is suitable for routine monitoring of antifungal therapy and in severely ill patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000438","type":"journal-article","created":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T19:59:48Z","timestamp":1501012788000},"page":"505-513","source":"Crossref","is-referenced-by-count":24,"title":["Reliable and Easy-To-Use Liquid Chromatography\u2013Tandem Mass Spectrometry Method for Simultaneous Analysis of Fluconazole, Isavuconazole, Itraconazole, Hydroxy-Itraconazole, Posaconazole, and Voriconazole in Human Plasma and Serum"],"prefix":"10.1097","volume":"39","author":[{"given":"Carsten","family":"M\u00fcller","sequence":"first","affiliation":[{"name":"Center of Pharmacology, Therapeutic Drug Monitoring, University Hospital of Cologne, Cologne;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gehlen","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Cologne, Cologne;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Blaich","sequence":"additional","affiliation":[{"name":"Center of Pharmacology, Therapeutic Drug Monitoring, University Hospital of Cologne, Cologne;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenik","family":"Prozeller","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Cologne, Cologne;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blasius","family":"Liss","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital of Cologne, Cologne; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Streichert","sequence":"additional","affiliation":[{"name":"Institute for Clinical Chemistry, University Hospital of Cologne, Cologne, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H. J.","family":"Wiesen","sequence":"additional","affiliation":[{"name":"Center of Pharmacology, Therapeutic Drug Monitoring, University Hospital of Cologne, Cologne;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230928","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British society for medical mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother."},{"key":"R2-20230928","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1515\/cclm-2014-1108","article-title":"Multi-analyte analysis of non-vitamin K antagonist oral anticoagulants in human plasma using tandem mass spectrometry","volume":"53","author":"Blaich","year":"2015","journal-title":"Clin Chem Lab Med."},{"key":"R3-20230928","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1007\/BF02493365","article-title":"LC-MS-MS experiences with internal standards","volume":"55","author":"Wieling","year":"2002","journal-title":"Chromatographia."},{"key":"R7-20230928","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal Chem."},{"key":"R9-20230928","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/FTD.0b013e3181b20b40","article-title":"A rapid and sensitive LC-MS\/MS method for determination of fluconazole in human plasma and its application in infants with Candida infections","volume":"31","author":"Wu","year":"2009","journal-title":"Ther Drug Monit."},{"key":"R10-20230928","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1039\/C6AY00879H","article-title":"Determination of isavuconazole in rat plasma by UPLC-MS\/MS: application to a pharmacokinetic study","volume":"8","author":"Liang","year":"2016","journal-title":"Anal Methods."},{"key":"R11-20230928","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.chroma.2003.11.061","article-title":"Simultaneous determination of itraconazole and hydroxyitraconazole in human plasma by high-performance liquid chromatography","volume":"1031","author":"Srivatsan","year":"2004","journal-title":"J Chromatogr A."},{"key":"R12-20230928","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jpba.2009.03.034","article-title":"A high-throughput LC-MS\/MS method for the quantitation of posaconazole in human plasma: implementing fused core silica liquid chromatography","volume":"50","author":"Cunliffe","year":"2009","journal-title":"J Pharm Biomed Anal."},{"key":"R13-20230928","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cca.2012.01.008","article-title":"Fast and simple LC-MS\/MS method for quantifying plasma voriconazole","volume":"413","author":"Pauwels","year":"2012","journal-title":"Clin Chim Acta."},{"issue":"suppl 3","key":"R14-20230928","doi-asserted-by":"crossref","first-page":"S318","DOI":"10.1093\/clinids\/12.Supplement_3.S318","article-title":"Pharmacokinetics and tissue penetration of fluconazole in humans","volume":"12","author":"Brammer","year":"1990","journal-title":"Rev Infect Dis."},{"key":"R15-20230928","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1093\/ndt\/gfg363","article-title":"Dosing guidelines for fluconazole in patients with renal failure","volume":"18","author":"Cousin","year":"2003","journal-title":"Nephrol Dial Transpl."},{"key":"R16-20230928","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica."},{"key":"R18-20230928","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/MCP.0b013e32833e24a6","article-title":"Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosis","volume":"16","author":"Moss","year":"2010","journal-title":"Curr Opin Pulm Med."},{"key":"R19-20230928","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/jac\/dks268","article-title":"A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers","volume":"67","author":"Krishna","year":"2012","journal-title":"J Antimicrob Chemother."},{"key":"R20-20230928","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/clpt.2010.64","article-title":"Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma","volume":"88","author":"Jang","year":"2010","journal-title":"Clin Pharmacol Ther."},{"key":"R21-20230928","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1128\/AAC.00815-12","article-title":"Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease","volume":"56","author":"Tonini","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"key":"R22-20230928","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med."},{"key":"R23-20230928","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med."},{"key":"R24-20230928","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1128\/AAC.00496-15","article-title":"Retrospective comparison of posaconazole levels in patients taking the delayed-release tablet versus the oral suspension","volume":"59","author":"Durani","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"R25-20230928","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1128\/AAC.00163-06","article-title":"In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts","volume":"50","author":"Sabatelli","year":"2006","journal-title":"Antimicrob Agents Chemother."},{"key":"R26-20230928","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1086\/367933","article-title":"Voriconazole: a new triazole antifungal agent","volume":"36","author":"Johnson","year":"2003","journal-title":"Clin Infect Dis."},{"key":"R27-20230928","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jchromb.2009.11.017","article-title":"Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC\/MS\/MS","volume":"878","author":"Alffenaar","year":"2010","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R28-20230928","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.cca.2011.09.042","article-title":"Rapid HPLC-MS\/MS method for simultaneous quantitation of four routinely administered triazole antifungals in human plasma","volume":"413","author":"Beste","year":"2012","journal-title":"Clin Chim Acta."},{"key":"R29-20230928","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/FTD.0b013e3182381bb1","article-title":"Measurement of posaconazole, itraconazole, and hydroxyitraconazole in plasma\/serum by high-performance liquid chromatography with fluorescence detection","volume":"33","author":"Buckner","year":"2011","journal-title":"Ther Drug Monit."},{"key":"R30-20230928","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00216-012-6176-3","article-title":"An automated method for the simultaneous measurement of azole antifungal drugs in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry","volume":"404","author":"Couchman","year":"2012","journal-title":"Anal Bioanal Chem."},{"key":"R31-20230928","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1128\/AAC.00404-10","article-title":"Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin","volume":"54","author":"Decosterd","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"key":"R32-20230928","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1128\/AAC.01276-09","article-title":"Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry","volume":"54","author":"Farowski","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"key":"R33-20230928","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1093\/ajcp\/aqw191.020","article-title":"Therapeutic drug monitoring of azole antifungal medications by liquid chromatography-tandem mass spectrometry","volume":"147","author":"McShane","year":"2017","journal-title":"Am J Clin Pathol."},{"key":"R34-20230928","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jchromb.2017.01.036","article-title":"An ultra performance liquid chromatography-tandem mass spectrometry method for the therapeutic drug monitoring of isavuconazole and seven other antifungal compounds in plasma samples","volume":"1046","author":"Toussaint","year":"2017","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R35-20230928","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1515\/CCLM.2010.252","article-title":"Liquid chromatography-tandem mass spectrometry method for simultaneous quantification of four triazole antifungal agents in human plasma","volume":"48","author":"Verdier","year":"2010","journal-title":"Clin Chem Lab Med."},{"key":"R36-20230928","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jchromb.2012.01.015","article-title":"Simultaneous determination of the azoles voriconazole, posaconazole, isavuconazole, itraconazole and its metabolite hydroxy-itraconazole in human plasma by reversed phase ultra-performance liquid chromatography with ultraviolet detection","volume":"887\u2013888","author":"Wissen","year":"2012","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R37-20230928","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1515\/cclm-2012-0364","article-title":"Validation of a fast and reliable liquid chromatography-tandem mass spectrometry (LC-MS\/MS) with atmospheric pressure chemical ionization method for simultaneous quantitation of voriconazole, itraconazole and its active metabolite hydroxyitraconazole in human plasma","volume":"51","author":"Xiong","year":"2013","journal-title":"Clin Chem Lab Med."},{"key":"R38-20230928","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1039\/C3AY42010H","article-title":"Solid-phase membrane tip extraction combined with liquid chromatography for the determination of azole antifungal drugs in human plasma","volume":"6","author":"Yahaya","year":"2014","journal-title":"Anal Methods."},{"key":"R39-20230928","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1128\/AAC.00768-12","article-title":"A simple high-performance liquid chromatography method for simultaneous determination of three triazole antifungals in human plasma","volume":"57","author":"Zhang","year":"2013","journal-title":"Antimicrob Agents Chemother."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201710000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T01:04:31Z","timestamp":1695863071000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201710000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000438","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]}}}